Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

On March 11, Pfizer and Arvinas, a clinical-stage biotechnology company, announced promising results from a late-stage trial for vepdegestrant, a new experimental oral drug for advanced breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE:PFE) today announced positive topline results from the Phase 3 VERITAC-2 ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...

Pfizer has disappointed investors for the past three years, but its low valuation could make it attractive now. Its sales may decline a bit in 2025, but management has been targeting long-term ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new awareness campaign for pneumococcal pneumonia vaccination. Toward the end ...

Arvinas, Inc. (NASDAQ ... The company’s lead program, vepdegestrant (vepdeg), is being developed with Pfizer as a potential best-in-class ER-targeting backbone therapy for breast cancer treatment.

Pfizer and Arvinas have shared promising top-line results from a late-stage study of their investigational protein degrader vepdegestrant in a subset of breast cancer patients. The phase 3 VERITAC-2 ...